Advanced Squamous-Cell Carcinoma of the Trachea in Patients Not Eligible for Radical Treatment
Clinical Scenario
Squamous-cell carcinoma (SCC) is the predominant histology of primary tracheal carcinomas and is typical of smokers and men over 60 years of age. When the disease is advanced and the patient is not a candidate for radical treatment — whether due to disease extent or patient fitness — the clinical priority shifts to palliative management.
Treatment Approach (partial overview)
For advanced tracheal SCC in this setting, a platinum-based chemotherapy strategy is the established palliative option. Enrolment in clinical trials evaluating chemotherapy in combination with immune checkpoint inhibitors may also be considered.
The full structured regimen — including agent selection, sequencing, and clinical trial criteria — is available in the complete protocol.
References
- Squamous cell carcinoma is the predominant histology of primary tracheal carcinomas, typical of smokers and men over 60 years of age.
- Consider platinum-based chemotherapy as a palliative option for patients with advanced SCC who are not candidates for radical treatment [II, B].
- Consider enrolling in clinical trials investigating the combination of chemotherapy with immune checkpoint inhibitors for patients with advanced SCC [II, B].
- Treatment combining platinum-based chemotherapy with immune checkpoint inhibitors - toripalimab, nivolumab - remains an area of discussion and provided clinical trials NCT04716751, NCT05964101, NCT02834013.
DOI: 10.3389/or.2024.1451247
View source ↗